Moderna says its COVID-19 vaccine protective, safe in young children

Moderna says its COVID-19 vaccine protective, safe in young children Moderna Inc said on Monday its COVID-19 vaccine generated a strong immune response and was generally well-tolerated in children aged six to 11 years, and the company plans to submit the data to regulators soon. Reuters Reuters

Oct 25 (Reuters) - Moderna Inc (MRNA.O) said on Monday its COVID-19 vaccine generated a strong immune response and was generally well-tolerated in children aged six to 11 years, and the company plans to submit the data to regulators soon.

Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and safety was comparable to what was previously seen in clinical trials of adolescents and adults.

A panel of FDA advisers will vote on Tuesday whether to authorize rival Pfizer (PFE.N) and BioNTech's COVID-19 vaccine for use in children aged five to 11 years. ...